Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — Q2 2024 Earnings Presentation
24 slides from Expres2ion Biotech Holding Ab's earnings presentation, Aug 15, 2024
Slide 1: Q2 2024 earnings presentation
healthier world Hosted by & HH ANDERSEN ExpreS2ion Biotech Holding AB CAPITAL Org, Nr. $59033-3729
Slide 2: Agenda
expreSeion BIOTECH Agenda * Management discussion & analysis * Financial results * Q&SA
Slide 3: Management discussion & analysis
discussion & analysis
Slide 4: Major news since Q1
expreSeion BIOTECH Major news since Q1 Dividend of mSEK 22.5 paid + Following their receipt of a €10M milestone payment from Bavarian Nordic for by AdaptVac completion of Phase 3 activities for the ABNCoV2 COVID-19 vaccine Gross proceeds from rights + Potential further proceeds from warrant schemes
Slide 5: Vaccine pipeline
Vaccine pipeline Programs that are controlled or semi-controlled by ExpreS2ion expreSceion BIOTECH Discovery Lead opt CTA-enabling Phi Ph2 Ph3. Market size ES2B-C001 >€10 HER2+ breast cancer Oncology Billion! (therapeutic) ee be . ESZB-|002 Infectious >€2 ® Cytomegalovirus disease Billion? 7? (preve
Slide 6: ES2B-C001 - a breakthrough BC vaccine
expreSeion ES2B-CO01 - a breakthrough BC vaccine “me Based on technology with clinical PoC and Phase III validation (COVID-19) « VLP concept in approved vaccines HER2 protein . HPV vaccine against cervical cancer and HBV (all 4 extra-cellular sub domains) vaccine against liver cancer ExpreS2™ platfo
Slide 7: ES2B-C001 update
ES2B-CO01 update Significant progress, on path towards first-in-human clinical Phase | trial with HER2-VLP Scientific advice meeting with regulatory agency Finalization of Phase | Manufacture Manufacture Finalization Selection of and release and release Finalization of Phase | clinical trial protoco
Slide 8: First-in-human Phase I clinical trial
expreSceion BIOTECH First-in-human Phase | clinical trial Clinical study (ES2B-C001-S1) protocol title Gabi A first-in-human phase |, open-label, dose-escalating trial to assess the safety, tolerability and immunogenicity / preliminary antitumor activity of ES2B-CO001, with or without Montanide, in
Slide 9: ES2B-C001-S1 study objectives
expreScion BIOTECH ES2B-COO1-S1 study objectives Primary Objective * To determine the safety, tolerability, maximum tolerated dose (MTD) for ES2B-C001 alone or in combination with the adjuvant Montanide. Secondary Objectives * To investigate the immunogenicity of ES2B-C001 alone or in combination wi
Slide 10: ES2B-C001-S1 study design
ES2B-CO0O1-S1 study design Investigational Medicinal Product (IMP) to be tested in adapted 3+3 design * Two treatment groups * Non-adjuvanted and adjuvanted * Each group testing up to three different doses/cohorts * Enrollment staggered in each cohort * 18 patients (3 per cohort) to be enrolled * Pl
Slide 11: ES2B-C001 - Strategy to market
expreScion BIOTECH ES2B-CO01 - Strategy to market Taking an active B2B approach in prolongation of clinical proof of concept (PoC) Partnering Preferably Big Pharma TE expre S clon Pharmaceutical Ey Medical centres =} Company (licensor) (customers) R&D, early clinical validation, IP management, Phase
Slide 12: Upcoming events
Upcoming events Opportunities to learn more about specific projects and interact with management 2 September, Aarhus * Association of Listed Growth Companies (FBV) Pitch Event 12 September, Stockholm + Institutional Investor Meeting 17 September, Copenhagen + Institutional Investor Seminar <= HC AND
Slide 13: Financial results
Financial results
Slide 14: Summary of 2024 first half results
Summary of 2024 first half results expreSeion BIOTECH Key income statement figures, SEK ‘000s Operating income Profit/loss after financial items Profit/loss Key balance sheet figures, SEK ‘000s Cash balance, end of period Total assets, end of period Equity/asset ratio, end of period (%)* Number of s
Slide 15: Net sales and other operating income
Net sales Other operating income 1Q22 3Q22 1Q23 3Q23 1Q24 1Q22 3Q22 1Q23 3Q23 1Q24
Slide 16: Operating costs
expreSeion ° BIOTECH Operating costs SEK ‘OOOs 10) -10.000 i | -20.000 -30.000 a -40.000 — ~35% -50.000 -60.000 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 1Q24 2Q24 16
Slide 17: -10.000 -20.000 -30.000 -40.000
0 -10.000 -20.000 -30.000 -40.000
Slide 18: Profit / loss for the period
Profit / loss for the period SEK ‘000s 2Q profit / loss 30.000 2.537 |] -30.000 50.038 non -108% -60.000 -90.000 -120.000 -150.000 2023 2024 expreSeion BIOTECH Year-to-date profit / loss ° a -10.316 -30.000 ~60.000 =56.346 a -90.000 -120.000 -150.000 2023 2024 18
Slide 19: Cash development, first half of 2024
Cash development, first half of 2024 expreSeion BIOTECH SEK millions 80 70 ral 0 69 58 -1 60 40 8 Approximately SEK 30 million 30 Gross proceeds from rights issue completed after end of second quarter 2024 20 10 ie} December 2023 Operations Investing Financing FX June 2024 19
Slide 20: 1Q22 2Q22 3Q22 4Q22 1Q23 Q23 3Q23 4Q23 1Q24 2Q24
168 150 125 111 88 77 72 69 58 60 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 1Q24 2Q24
Slide 21: Looking forward: warrant subscriptions
expreSeion Looking forward Biorech TO 10 warrant subscription + Subscription: November 20 - December 4, 2024 + Terms: 1 warrant = 1 new share + Price: 70% of the VWAP during 1-14 November 2024 * Cap: SEK 1.50 + Floor: SEK 0.11111 (equal to quota value) TO 11 warrant subscription + Subscription: Sept
Slide 22: Q&A
Slide 23: Disclaimer
expreScion BIOTECH Disclaimer This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise acquire, any shares or any other securities in ExpreS2ion Biotech Holding AB (the "Company"). Neither shall the presentati
Slide 24: Investor Relations
Investor Relations
ExpreS2ion Biotech Holding — Q2 2024 Earnings Presentation on 6ix